MedPath

Subcutaneous Isatuximab Plus Pd Shows Promise in R/R Multiple Myeloma Treatment

Recent clinical trials reveal that subcutaneous isatuximab combined with Pd meets coprimary endpoints and is noninferior to IV administration in treating relapsed/refractory multiple myeloma, marking a significant advancement in care.

In a groundbreaking development for the treatment of relapsed/refractory multiple myeloma (RRMM), subcutaneous isatuximab plus Pd has demonstrated noninferiority in overall response rate (ORR) and observed concentration before dosing at steady state compared to its intravenous (IV) counterpart. This finding, reported on January 9th, 2025, signifies a pivotal shift towards more accessible and potentially less burdensome treatment options for patients.
Moreover, the Mayo Clinic has been at the forefront of revolutionizing multiple myeloma care, with a dedicated professional who has significantly contributed to the field. This individual's journey from a late interest in medicine to becoming a key figure in multiple myeloma research underscores the dynamic and evolving nature of cancer treatment and care.
These advancements highlight the ongoing efforts and progress in the fight against multiple myeloma, offering hope and improved quality of life for patients worldwide.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Multiple Myeloma Treatment Advances: Belantamab Mafodotin's Comeback and New FDA Approvals

Belantamab mafodotin (Blenrep) was resurrected after being pulled from the market, demonstrating efficacy in combination therapies for relapsed/refractory multiple myeloma.
Subcutaneous daratumumab-hyaluronidase (Darzalex Faspro) received FDA approval in combination with VRd for newly diagnosed multiple myeloma patients eligible for autologous stem cell transplant.

FDA Updates: Approvals and Designations in Leukemia, Prostate Cancer, and Melanoma

Capivasertib plus abiraterone and ADT shows improved radiographic progression-free survival in PTEN-deficient metastatic hormone-sensitive prostate cancer.
LBS-007 receives FDA fast track designation for acute myeloid leukemia treatment based on promising early response data from a phase 1/2 trial.

Osimertinib Recommended for EU Approval in Locally Advanced EGFR-Mutated NSCLC After Chemoradiation

The European Medicines Agency's CHMP recommended osimertinib for unresectable EGFR-mutated NSCLC after platinum-based chemoradiation.
The recommendation is based on the Phase 3 LAURA trial, which showed an 84% reduction in disease progression or death with osimertinib versus placebo.

Ensartinib Approved by FDA for First-Line ALK-Positive Non-Small Cell Lung Cancer

The FDA has approved ensartinib (Ensacove) for first-line treatment of ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).
Ensartinib demonstrated statistically significant improvement in progression-free survival compared to crizotinib in the eXALT3 trial.

Osimertinib-Based Regimens Lead Evolving Treatment Strategies for EGFR-Mutated NSCLC

Osimertinib, alone or with chemotherapy, is now a preferred first-line treatment for EGFR-mutated NSCLC, particularly for patients with brain metastases.
The FLAURA2 trial demonstrated improved progression-free survival with osimertinib plus chemotherapy, leading to its integration into NCCN guidelines.

Durvalumab Shows Promise in Resectable NSCLC Treatment

Durvalumab receives MHRA approval in Great Britain for resectable non-small cell lung cancer (rNSCLC) treatment in combination with platinum-based chemotherapy.
The AEGEAN Phase III trial data showed a 32% reduction in the risk of recurrence, progression, or death with durvalumab-based treatment before and after surgery.

Emavusertib-Based Therapy Shows Promise in BTK Inhibitor-Refractory PCNSL

Emavusertib, an IRAK4 and FLT3 inhibitor, has shown potential in overcoming resistance to BTK inhibitors in primary central nervous system lymphoma (PCNSL).
The TakeAim Lymphoma trial is evaluating emavusertib in combination with ibrutinib for relapsed/refractory PCNSL, demonstrating encouraging early responses in BTK inhibitor-refractory patients.

Perioperative Nivolumab and Neoadjuvant Immunotherapy Show Promise in Resectable NSCLC

Perioperative nivolumab significantly extends event-free survival (EFS) in resectable NSCLC, with a median EFS increase from 17.0 to 40.1 months.
Neoadjuvant nivolumab, alone or with ipilimumab, demonstrates durable long-term survival benefits, particularly in patients achieving major pathological response (MPR) or pathological complete response (PCR).

Aggressive Supportive Care May Reduce Infection Risk Following Linvoseltamab Treatment in Multiple Myeloma

Aggressive supportive care is crucial following linvoseltamab and BCMA bispecific antibody treatments to prevent high-grade infections, especially in community settings.
Intravenous immunoglobulin and infection prophylaxis are essential components of supportive care to mitigate the risk of severe infections post-immunotherapy.

EHA 2024: Monoclonal Antibodies Show Promise in Multiple Myeloma Treatment

The DREAMM-8 trial demonstrated that Blenrep combined with pomalidomide and dexamethasone significantly improved progression-free survival in relapsed/refractory multiple myeloma (RRMM) patients compared to pomalidomide, bortezomib, and dexamethasone.
Linvoseltamab monotherapy in the LINKER-MM1 study showed substantial efficacy in RRMM patients, with a high objective response rate and durable responses, marking it as a promising treatment option.

Reference News

[1]
Multiple Myeloma | Clinical Oncology News
onclive.com · Nov 10, 2020

Sunvozertinib receives priority review for EGFR-mutated NSCLC. Subcutaneous isatuximab plus Pd shows noninferiority to I...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy